Support our Foundation of Myology project
ATA-003-GSAR (Atamyo)
A phase 1-2, open-label, dose-escalation study to evaluate the safety of three doses of intravenous ATA-200, an adeno-associated viral vector carrying the human gamma-sarcoglycan gene, in patients with gamma-sarcoglycanopathy (LGMD R5, formerly LGMD 2C).